{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:33Z","timestamp":1781639613459,"version":"3.54.5"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wellcome Career Development Award","award":["227228\/Z\/23\/Z"],"award-info":[{"award-number":["227228\/Z\/23\/Z"]}]},{"name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas, FONDO SECTORIAL DE INVESTIGACI\u00d3N PARA LA EDUCACI\u00d3N","award":["A1-S-30165, I1200\/169\/2019"],"award-info":[{"award-number":["A1-S-30165, I1200\/169\/2019"]}]},{"name":"Programa de apoyo a proyectos de investigaci\u00f3n e innovaci\u00f3n tecnol\u00f3gica (PAPIIT).","award":["IN228525"],"award-info":[{"award-number":["IN228525"]}]},{"name":"\u2022\tPrograma de apoyo a proyectos de investigaci\u00f3n e innovaci\u00f3n tecnol\u00f3gica (PAPIIT).","award":["IN228525"],"award-info":[{"award-number":["IN228525"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD (non-alcoholic fatty liver disease), is a growing global concern, affecting nearly a third of the world\u2019s population. This umbrella term covers a range of liver pathologies, from reversible disease stages like simple steatosis, to irreversible conditions such as cirrhosis and hepatocellular carcinoma (HCC). MASLD, which may result from metabolic risk factors like obesity and type 2 diabetes, is projected to increase due to a rise in sedentary lifestyles. This review addresses genetic influences that predispose to disease development, including the role of risk-conferring and protective\/preventive alleles. The epistatic relationships between genetic variants can significantly influence the development and progression of MASLD. Key genetic variants, such as those located in the\n                    <jats:italic>PNPLA3<\/jats:italic>\n                    ,\n                    <jats:italic>TM6SF2<\/jats:italic>\n                    , and\n                    <jats:italic>MBOAT7<\/jats:italic>\n                    genes, often interact to exacerbate MASLD severity and play key roles in lipid metabolism and liver inflammation. For example, the co-expression of certain\n                    <jats:italic>PNPLA3<\/jats:italic>\n                    and\n                    <jats:italic>TM6SF2<\/jats:italic>\n                    variants increases the risk of advanced fibrosis and HCC. Some variants located in\n                    <jats:italic>HSD17B13<\/jats:italic>\n                    and\n                    <jats:italic>MTARC1<\/jats:italic>\n                    offer protective effects, reducing the risk of severe liver disease despite comorbidities such as obesity, and can mitigate the harmful effects of these risk alleles. Additionally, the potential of polygenic risk scores (PRS) to predict MASLD development and its complications is also discussed, although challenges remain, particularly in underrepresented populations due to the lack of comprehensive catalogues of genetic variation. Understanding these complex gene-gene interactions and the role of the environment underscores the importance of considering epistatic relationships when assessing MASLD risk and developing personalized therapeutic strategies, which could ease the future burden on healthcare systems.\n                  <\/jats:p>","DOI":"10.1186\/s12920-026-02332-7","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:17:20Z","timestamp":1772443040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes"],"prefix":"10.1186","volume":"19","author":[{"given":"Fernanda G.","family":"Arriaga-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Jes\u00fas Casta\u00f1eda-C\u00f3rdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"D\u00edaz-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Daniela","family":"Robles-Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Molina-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2332_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2332_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.026","author":"AM Allen","year":"2023","unstructured":"Allen AM, Lazarus JV, Younossi ZM. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.026. :S0168-8278(23)00079-X.","journal-title":"J Hepatol"},{"key":"2332_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577\u201386. https:\/\/doi.org\/10.1002\/hep.28785.","journal-title":"Hepatology"},{"key":"2332_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775\u201382. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.024.","journal-title":"J Hepatol"},{"key":"2332_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. IJERPH. 2021;18:5227. https:\/\/doi.org\/10.3390\/ijerph18105227.","journal-title":"IJERPH"},{"key":"2332_CR6","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/jcm12051852","volume":"12","author":"M Kosmalski","year":"2023","unstructured":"Kosmalski M, Frankowski R, Zi\u00f3\u0142kowska S, R\u00f3\u017cycka-Kosmalska M, Pietras T. What\u2019s new in the treatment of non-alcoholic fatty liver disease (NAFLD). JCM. 2023;12:1852. https:\/\/doi.org\/10.3390\/jcm12051852.","journal-title":"JCM"},{"key":"2332_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/nu13051442","volume":"13","author":"P Vancells Lujan","year":"2021","unstructured":"Vancells Lujan P, Vi\u00f1as Esmel E, Sacanella Meseguer E. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients. 2021;13:1442. https:\/\/doi.org\/10.3390\/nu13051442.","journal-title":"Nutrients"},{"key":"2332_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082986","volume":"21","author":"M Meroni","year":"2020","unstructured":"Meroni M, Longo M, Rustichelli A, Dongiovanni P. Nutrition and genetics in NAFLD: the perfect binomium. IJMS. 2020;21:2986. https:\/\/doi.org\/10.3390\/ijms21082986.","journal-title":"IJMS"},{"key":"2332_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/JHC.S272213","volume":"8","author":"D Geh","year":"2021","unstructured":"Geh D, Anstee QM, Reeves HL. NAFLD-associated HCC: progress and opportunities. J Hepatocell Carcinoma. 2021;8:223\u201339. https:\/\/doi.org\/10.2147\/JHC.S272213.","journal-title":"J Hepatocell Carcinoma"},{"key":"2332_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72:1196\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.020.","journal-title":"J Hepatol"},{"key":"2332_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","volume":"21","author":"D Ochoa","year":"2022","unstructured":"Ochoa D, Karim M, Ghoussaini M, Hulcoop DG, McDonagh EM, Dunham I. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov. 2022;21:551. https:\/\/doi.org\/10.1038\/d41573-022-00120-3.","journal-title":"Nat Rev Drug Discov"},{"key":"2332_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.24309","volume":"43","author":"S Gudmundsson","year":"2022","unstructured":"Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: lessons from gnomAD. Hum Mutat. 2022;43:1012\u201330. https:\/\/doi.org\/10.1002\/humu.24309.","journal-title":"Hum Mutat"},{"key":"2332_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135. https:\/\/doi.org\/10.1038\/ng.257.","journal-title":"Nat Genet"},{"key":"2332_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.metabol.2015.08.018","volume":"65","author":"P Dongiovanni","year":"2016","unstructured":"Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism. 2016;65:1026\u201337. https:\/\/doi.org\/10.1016\/j.metabol.2015.08.018.","journal-title":"Metabolism"},{"key":"2332_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","volume":"72","author":"M M\u00fcller","year":"2020","unstructured":"M\u00fcller M, Bird TG, Nault J-C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72:990\u20131002. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.019.","journal-title":"J Hepatol"},{"key":"2332_CR16","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","volume":"19","author":"P Dongiovanni","year":"2013","unstructured":"Dongiovanni P. PNPLA3 I148M polymorphism and progressive liver disease. WJG. 2013;19:6969. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6969.","journal-title":"WJG"},{"key":"2332_CR17","doi-asserted-by":"publisher","unstructured":"Kim DY, Park JY. Genetic risk factors associated with NAFLD. HR. 2020;2020. https:\/\/doi.org\/10.20517\/2394-5079.2020.96","DOI":"10.20517\/2394-5079.2020.96"},{"key":"2332_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101111","volume":"50","author":"W Jonas","year":"2021","unstructured":"Jonas W, Sch\u00fcrmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2021;50:101111. https:\/\/doi.org\/10.1016\/j.molmet.2020.101111.","journal-title":"Mol Metab"},{"key":"2332_CR19","doi-asserted-by":"publisher","unstructured":"Park J, Zhao Y, Zhang F, Zhang S, Kwong AC, Zhang Y et al. IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol. 2022;:S0168827822030537. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.022","DOI":"10.1016\/j.jhep.2022.08.022"},{"key":"2332_CR20","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1210\/clinem\/dgaa729","volume":"106","author":"PK Luukkonen","year":"2021","unstructured":"Luukkonen PK, Qadri S, Lehtim\u00e4ki TE, Juuti A, Sammalkorpi H, Penttil\u00e4 AK, et al. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. J Clin Endocrinol Metabolism. 2021;106:e300\u201315. https:\/\/doi.org\/10.1210\/clinem\/dgaa729.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2332_CR21","unstructured":"Arrese M, Arab JP, Riquelme A, Ben\u00edtez CE, Barrera F, Soza A et al. High prevalence of PNPLA3 rs738409 (I148M) polymorphism in Chilean latino population and its association to non-alcoholic fatty liver disease risk and histological disease severity. 2015. https:\/\/repositorio.uchile.cl\/bitstream\/handle\/2250\/137175\/High-prevalence-of-PNPLA3-RESTRINGIDO.pdf?sequence=1&isAllowed=y."},{"key":"2332_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12863-015-0255-3","volume":"16","author":"AC Pontoriero","year":"2015","unstructured":"Pontoriero AC, Trinks J, Hulaniuk ML, Caputo M, Fortuny L, Pratx LB, et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genet. 2015;16:93. https:\/\/doi.org\/10.1186\/s12863-015-0255-3.","journal-title":"BMC Genet"},{"key":"2332_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5604\/01.3001.0010.5282","volume":"16","author":"LA Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez LA, Larrieta E, Kershenobich D, Torre A. The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in Hispanic population. Ann Hepatol. 2017;16:909\u201315. https:\/\/doi.org\/10.5604\/01.3001.0010.5282.","journal-title":"Ann Hepatol"},{"key":"2332_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cncr.35000","volume":"130","author":"N Acuna","year":"2024","unstructured":"Acuna N, Zhou K, Pinheiro PS, Cheng I, Shariff-Marco S, Lim T, et al. Increasing risk of hepatocellular carcinoma with successive generations in the United States among Mexican American adults: the Multiethnic Cohort. Cancer. 2024;130:267\u201375. https:\/\/doi.org\/10.1002\/cncr.35000.","journal-title":"Cancer"},{"key":"2332_CR25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jhep.2020.01.029","volume":"72","author":"RW Walker","year":"2020","unstructured":"Walker RW, Belbin GM, Sorokin EP, Van Vleck T, Wojcik GL, Moscati A, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol. 2020;72:1070\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.029.","journal-title":"J Hepatol"},{"key":"2332_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136. https:\/\/doi.org\/10.1038\/ng.2901.","journal-title":"Nat Genet"},{"key":"2332_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/hep4.1822","volume":"6","author":"F Luo","year":"2022","unstructured":"Luo F, Oldoni F, Das A. TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease. Hepatol Commun. 2022;6:448\u201360. https:\/\/doi.org\/10.1002\/hep4.1822.","journal-title":"Hepatol Commun"},{"key":"2332_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/17474124.2022.2032661","volume":"16","author":"W-Y Xue","year":"2022","unstructured":"Xue W-Y, Zhang L, Liu C-M, Gao Y, Li S-J, Huai Z-Y, et al. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2022;16:97\u2013107. https:\/\/doi.org\/10.1080\/17474124.2022.2032661.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2332_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144079","volume":"5","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Adiels M, Bj\u00f6rnson E, Matikainen N, S\u00f6derlund S, R\u00e4m\u00f6 J, et al. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight. 2020;5:e144079. https:\/\/doi.org\/10.1172\/jci.insight.144079.","journal-title":"JCI Insight"},{"key":"2332_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47737-w","volume":"9","author":"S Prill","year":"2019","unstructured":"Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep. 2019;9:11585. https:\/\/doi.org\/10.1038\/s41598-019-47737-w.","journal-title":"Sci Rep"},{"key":"2332_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12852","author":"KJ Lee","year":"2022","unstructured":"Lee KJ, Moon JS, Kim NY, Ko JS. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children. Pediatr Obes. 2022. https:\/\/doi.org\/10.1111\/ijpo.12852.","journal-title":"Pediatr Obes"},{"issue":"8","key":"2332_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.02.012","volume":"55","author":"L Balcar","year":"2023","unstructured":"Balcar L, Scheiner B, Urheu M, Weinberger P, Paternostro R, Simbrunner B, et al. The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease. Dig Liver Dis. 2023;S1590865823002268. https:\/\/doi.org\/10.1016\/j.dld.2023.02.012.","journal-title":"Dig Liver Dis"},{"key":"2332_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102866","volume":"57","author":"M Meroni","year":"2020","unstructured":"Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine. 2020;57:102866. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102866.","journal-title":"EBioMedicine"},{"key":"2332_CR34","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants. Clin Gastroenterol Hepatol. 2022;20:e855\u201375. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2332_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","volume":"74","author":"K Teo","year":"2021","unstructured":"Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM. <article-title update=\"added\">rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol. 2021;74(1):20\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.027.","journal-title":"J Hepatol"},{"key":"2332_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100234","volume":"63","author":"V Varadharajan","year":"2022","unstructured":"Varadharajan V, Massey WJ, Brown JM. Membrane-bound O-acyltransferase 7 (MBOAT7)-driven phosphatidylinositol remodeling in advanced liver disease. J Lipid Res. 2022;63:100234. https:\/\/doi.org\/10.1016\/j.jlr.2022.100234.","journal-title":"J Lipid Res"},{"key":"2332_CR37","doi-asserted-by":"publisher","first-page":"1199429","DOI":"10.3389\/fendo.2023.1199429","volume":"14","author":"X Xu","year":"2023","unstructured":"Xu X, Xu H, Liu X, Zhang S, Cao Z, Qiu L, et al. MBOAT7 rs641738 (C\u2009>\u2009T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population. Front Endocrinol (Lausanne). 2023;14:1199429. https:\/\/doi.org\/10.3389\/fendo.2023.1199429.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2332_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338. https:\/\/doi.org\/10.1038\/s41575-020-00381-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2332_CR39","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.2174\/1871530320999201126202706","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Zhao Y, Zhang H, Hua W, Jiao W, Du X, et al. Contribution of Rs780094 and Rs1260326 polymorphisms in GCKR gene to non-alcoholic fatty liver disease: a meta-analysis involving 26,552 participants. Endocr Metab Immune Disord Drug Targets. 2021;21:1696\u2013708. https:\/\/doi.org\/10.2174\/1871530320999201126202706.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2332_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.971484","volume":"13","author":"NWS Chew","year":"2022","unstructured":"Chew NWS, Chong B, Ng CH, Kong G, Chin YH, Xiao W, et al. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front Genet. 2022;13:971484. https:\/\/doi.org\/10.3389\/fgene.2022.971484.","journal-title":"Front Genet"},{"key":"2332_CR41","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/2211-5463.13146","volume":"11","author":"Z Li","year":"2021","unstructured":"Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, et al. The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms. FEBS Open Bio. 2021;11:1893\u2013906. https:\/\/doi.org\/10.1002\/2211-5463.13146.","journal-title":"FEBS Open Bio"},{"key":"2332_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yexmp.2018.01.001","volume":"104","author":"E Larrieta-Carrasco","year":"2018","unstructured":"Larrieta-Carrasco E, Flores YN, Mac\u00edas-Kauffer LR, Ram\u00edrez-Palacios P, Quiterio M, Ram\u00edrez-Salazar EG, et al. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol. 2018;104:50\u20138. https:\/\/doi.org\/10.1016\/j.yexmp.2018.01.001.","journal-title":"Exp Mol Pathol"},{"key":"2332_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41387-018-0045-x","volume":"8","author":"J Yu","year":"2018","unstructured":"Yu J, Loh K, Song Z, Yang H, Zhang Y, Lin S. Update on glycerol-3-phosphate acyltransferases: the roles in the development of insulin resistance. Nutr Diabetes. 2018;8:34. https:\/\/doi.org\/10.1038\/s41387-018-0045-x.","journal-title":"Nutr Diabetes"},{"key":"2332_CR44","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1002\/hep.32038","volume":"74","author":"A Hakim","year":"2021","unstructured":"Hakim A, Moll M, Brancale J, Liu J, Lasky-Su JA, Silverman EK, et al. Genetic variation in the mitochondrial Glycerol-3-Phosphate Acyltransferase is associated with liver injury. Hepatology. 2021;74:3394\u2013408. https:\/\/doi.org\/10.1002\/hep.32038.","journal-title":"Hepatology"},{"key":"2332_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41594-022-00884-7","volume":"30","author":"ZL Johnson","year":"2023","unstructured":"Johnson ZL, Ammirati M, Wasilko DJ, Chang JS, Noell S, Foley TL, et al. Structural basis of the acyl-transfer mechanism of human GPAT1. Nat Struct Mol Biol. 2023;30:22\u201330. https:\/\/doi.org\/10.1038\/s41594-022-00884-7.","journal-title":"Nat Struct Mol Biol"},{"key":"2332_CR46","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","volume":"160","author":"O Jamialahmadi","year":"2021","unstructured":"Jamialahmadi O, Mancina RM, Ciociola E, Tavaglione F, Luukkonen PK, Baselli G, et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology. 2021;160:1634-1646.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.023.","journal-title":"Gastroenterology"},{"key":"2332_CR47","doi-asserted-by":"publisher","first-page":"S584","DOI":"10.1016\/S0168-8278(25)01578-8","volume":"82","author":"A Hakim","year":"2025","unstructured":"Hakim A, Schwantes-An T-HL, Zaborenko C, Abreu M, Guo X, Yao J, et al. FRI-336-YI Genetic variation in GPAM and protection against histologic severity in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;82:S584\u20135. https:\/\/doi.org\/10.1016\/S0168-8278(25)01578-8.","journal-title":"J Hepatol"},{"key":"2332_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","volume":"77","author":"GA Baselli","year":"2022","unstructured":"Baselli GA, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol. 2022;77:596\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.031.","journal-title":"J Hepatol"},{"key":"2332_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03939-w","volume":"9","author":"H Lim","year":"2018","unstructured":"Lim H, Lim Y-M, Kim KH, Jeon YE, Park K, Kim J, et al. A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nat Commun. 2018;9:1438. https:\/\/doi.org\/10.1038\/s41467-018-03939-w.","journal-title":"Nat Commun"},{"key":"2332_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021324","volume":"24","author":"A Barrientos-Riosalido","year":"2023","unstructured":"Barrientos-Riosalido A, Real M, Bertran L, Aguilar C, Mart\u00ednez S, Parada D, et al. Increased hepatic ATG7 mRNA and ATG7 protein expression in nonalcoholic steatohepatitis associated with obesity. Int J Mol Sci. 2023;24:1324. https:\/\/doi.org\/10.3390\/ijms24021324.","journal-title":"Int J Mol Sci"},{"key":"2332_CR51","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMra1910234","volume":"382","author":"P Strnad","year":"2020","unstructured":"Strnad P, McElvaney NG, Lomas DA. Alpha 1 -antitrypsin deficiency. N Engl J Med. 2020;382:1443\u201355. https:\/\/doi.org\/10.1056\/NEJMra1910234.","journal-title":"N Engl J Med"},{"key":"2332_CR52","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep4.1718","volume":"5","author":"A Hakim","year":"2021","unstructured":"Hakim A, Moll M, Qiao D, Liu J, Lasky-Su JA, Silverman EK, et al. Heterozygosity of the alpha 1\u2010antitrypsin Pi*Z allele and risk of liver disease. Hepatol Commun. 2021;5:1348\u201361. https:\/\/doi.org\/10.1002\/hep4.1718.","journal-title":"Hepatol Commun"},{"key":"2332_CR53","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0168-8278(00)80119-1","volume":"33","author":"H-P Fischer","year":"2000","unstructured":"Fischer H-P, Ortiz-Pallard\u00f3 ME, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous \u03b11-antitrypsin deficiency PiZ. J Hepatol. 2000;33:883\u201392. https:\/\/doi.org\/10.1016\/S0168-8278(00)80119-1.","journal-title":"J Hepatol"},{"key":"2332_CR54","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/gutjnl-2018-316228","volume":"68","author":"P Strnad","year":"2019","unstructured":"Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, et al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut. 2019;68:1099\u2013107. https:\/\/doi.org\/10.1136\/gutjnl-2018-316228.","journal-title":"Gut"},{"key":"2332_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1053\/j.gastro.2020.04.058","volume":"159","author":"CV Schneider","year":"2020","unstructured":"Schneider CV, Hamesch K, Gross A, Mandorfer M, Moeller LS, Pereira V, et al. Liver phenotypes of European adults heterozygous or homozygous for Pi\u2217Z variant of AAT (Pi\u2217MZ vs Pi\u2217ZZ genotype) and noncarriers. Gastroenterology. 2020;159:534-548.e11. https:\/\/doi.org\/10.1053\/j.gastro.2020.04.058.","journal-title":"Gastroenterology"},{"key":"2332_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2008.12.013","volume":"9","author":"J Ye","year":"2009","unstructured":"Ye J, Li JZ, Liu Y, Li X, Yang T, Ma X, et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab. 2009;9:177\u201390. https:\/\/doi.org\/10.1016\/j.cmet.2008.12.013.","journal-title":"Cell Metab"},{"key":"2332_CR57","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2337\/db07-0040","volume":"56","author":"JZ Li","year":"2007","unstructured":"Li JZ, Ye J, Xue B, Qi J, Zhang J, Zhou Z, et al. Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation. Diabetes. 2007;56:2523\u201332. https:\/\/doi.org\/10.2337\/db07-0040.","journal-title":"Diabetes"},{"key":"2332_CR58","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1194\/jlr.M026591","volume":"53","author":"X Li","year":"2012","unstructured":"Li X, Ye J, Zhou L, Gu W, Fisher EA, Li P. Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation. J Lipid Res. 2012;53:1877\u201389. https:\/\/doi.org\/10.1194\/jlr.M026591.","journal-title":"J Lipid Res"},{"key":"2332_CR59","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJMoa2117872","volume":"387","author":"N Verweij","year":"2022","unstructured":"Verweij N, Haas ME, Nielsen JB, Sosina OA, Kim M, Akbari P, et al. Germline mutations in CIDEB and protection against liver disease. N Engl J Med. 2022;387:332\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2117872.","journal-title":"N Engl J Med"},{"key":"2332_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/alcalc\/agz019","volume":"54","author":"C Mart\u00edn-Gonz\u00e1lez","year":"2019","unstructured":"Mart\u00edn-Gonz\u00e1lez C, Gonz\u00e1lez-Reimers E, Quintero-Platt G, Mart\u00ednez-Riera A, Santolaria-Fern\u00e1ndez F. Soluble \u03b1-Klotho in liver cirrhosis and alcoholism. Alcohol Alcohol. 2019;54:204\u20138. https:\/\/doi.org\/10.1093\/alcalc\/agz019.","journal-title":"Alcohol Alcohol"},{"key":"2332_CR61","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1038\/s41388-022-02440-5","volume":"41","author":"H Ligumsky","year":"2022","unstructured":"Ligumsky H, Merenbakh-Lamin K, Keren-Khadmy N, Wolf I, Rubinek T. The role of \u03b1-klotho in human cancer: molecular and clinical aspects. Oncogene. 2022;41:4487\u201397. https:\/\/doi.org\/10.1038\/s41388-022-02440-5.","journal-title":"Oncogene"},{"key":"2332_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","volume":"15","author":"OM Kuro","year":"2019","unstructured":"Kuro- OM. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15:27\u201344. https:\/\/doi.org\/10.1038\/s41581-018-0078-3.","journal-title":"Nat Rev Nephrol"},{"key":"2332_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3350\/cmh.2021.0301","volume":"28","author":"W-Y Liu","year":"2022","unstructured":"Liu W-Y, Zhang X, Li G, Tang L-J, Zhu P-W, Rios RS, et al. Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clin Mol Hepatol. 2022;28:183\u201395. https:\/\/doi.org\/10.3350\/cmh.2021.0301.","journal-title":"Clin Mol Hepatol"},{"key":"2332_CR64","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5223\/pghn.2019.22.3.233","volume":"22","author":"YH Cho","year":"2019","unstructured":"Cho YH, Kim JW, Shim JO, Yang HR, Chang JY, Moon JS, et al. Association between Vitamin D deficiency and suspected nonalcoholic fatty liver disease in an adolescent population. Pediatr Gastroenterol Hepatol Nutr. 2019;22:233\u201341. https:\/\/doi.org\/10.5223\/pghn.2019.22.3.233.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2332_CR65","doi-asserted-by":"publisher","unstructured":"PaolaDongiovanni. \u03b2-Klotho gene variation is associated with liver damage in children with NAFLD - ScienceDirect. J Hepatol 72:411\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.011","DOI":"10.1016\/j.jhep.2019.10.011"},{"key":"2332_CR66","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.18632\/aging.102293","volume":"11","author":"F Ji","year":"2019","unstructured":"Ji F, Liu Y, Hao J-G, Wang L-P, Dai M-J, Shen G-F, et al. KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese. Aging (Albany NY). 2019;11:7847\u201358. https:\/\/doi.org\/10.18632\/aging.102293.","journal-title":"Aging (Albany NY)"},{"key":"2332_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103249","volume":"65","author":"N Panera","year":"2021","unstructured":"Panera N, Meroni M, Longo M, Crudele A, Valenti L, Bellacchio E, et al. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine. 2021;65:103249. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103249.","journal-title":"EBioMedicine"},{"key":"2332_CR68","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.medj.2021.04.011","volume":"2","author":"CV Schneider","year":"2021","unstructured":"Schneider CV, Schneider KM, Conlon DM, Park J, Vujkovic M, Zandvakili I, et al. A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes. Med. 2021;2:851-863.e3. https:\/\/doi.org\/10.1016\/j.medj.2021.04.011.","journal-title":"Med"},{"key":"2332_CR69","doi-asserted-by":"publisher","first-page":"11958","DOI":"10.1073\/pnas.1808576115","volume":"115","author":"C Kubitza","year":"2018","unstructured":"Kubitza C, Bittner F, Ginsel C, Havemeyer A, Clement B, Scheidig AJ. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes. Proc Natl Acad Sci USA. 2018;115:11958\u201363. https:\/\/doi.org\/10.1073\/pnas.1808576115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2332_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008629","volume":"16","author":"CA Emdin","year":"2020","unstructured":"Emdin CA, Haas ME, Khera AV, Aragam K, Chaffin M, Klarin D, et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet. 2020;16:e1008629. https:\/\/doi.org\/10.1371\/journal.pgen.1008629.","journal-title":"PLoS Genet"},{"key":"2332_CR71","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/hep4.1955","volume":"6","author":"CA Hudert","year":"2022","unstructured":"Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, et al. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatol Commun. 2022;6:1934\u201348. https:\/\/doi.org\/10.1002\/hep4.1955.","journal-title":"Hepatol Commun"},{"key":"2332_CR72","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1053\/j.gastro.2020.06.014","volume":"159","author":"H Innes","year":"2020","unstructured":"Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, et al. Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1. Gastroenterology. 2020;159:1276-1289.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.014.","journal-title":"Gastroenterology"},{"key":"2332_CR73","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jhep.2015.10.016","volume":"64","author":"S Petta","year":"2016","unstructured":"Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2016;64:682\u201390. https:\/\/doi.org\/10.1016\/j.jhep.2015.10.016.","journal-title":"J Hepatol"},{"key":"2332_CR74","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/hmg\/ddw400","volume":"26","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, et al. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Hum Mol Genet. 2017;26:1747\u201358. https:\/\/doi.org\/10.1093\/hmg\/ddw400.","journal-title":"Hum Mol Genet"},{"key":"2332_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120473","volume":"7","author":"M Jim\u00e9nez-Sousa","year":"2018","unstructured":"Jim\u00e9nez-Sousa M, G\u00f3mez-Moreno A, Pineda-Tenor D, Brochado-Kith O, S\u00e1nchez-Ruano J, Artaza-Varasa T, et al. The Myeloid-Epithelial-Reproductive Tyrosine Kinase (MERTK) rs4374383 polymorphism predicts progression of liver fibrosis in hepatitis C virus-infected patients: a longitudinal study. JCM. 2018;7:473. https:\/\/doi.org\/10.3390\/jcm7120473.","journal-title":"JCM"},{"key":"2332_CR76","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1053\/j.gastro.2012.07.097","volume":"143","author":"E Patin","year":"2012","unstructured":"Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. 2012;143:1244-1252.e12. https:\/\/doi.org\/10.1053\/j.gastro.2012.07.097.","journal-title":"Gastroenterology"},{"key":"2332_CR77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","volume":"31","author":"B Cai","year":"2020","unstructured":"Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng Z, et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab. 2020;31:406-421.e7. https:\/\/doi.org\/10.1016\/j.cmet.2019.11.013.","journal-title":"Cell Metab"},{"key":"2332_CR78","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.31233","volume":"72","author":"Y Wen","year":"2020","unstructured":"Wen Y, Ju C. MER proto-oncogene tyrosine kinase: a novel potential target to treat nonalcoholic steatohepatitis fibrosis. Hepatology. 2020;72:772\u20134. https:\/\/doi.org\/10.1002\/hep.31233.","journal-title":"Hepatology"},{"key":"2332_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.824776","volume":"8","author":"H-B Zhang","year":"2021","unstructured":"Zhang H-B, Su W, Xu H, Zhang X-Y, Guan Y-F. HSD17B13: a potential therapeutic target for NAFLD. Front Mol Biosci. 2021;8:824776. https:\/\/doi.org\/10.3389\/fmolb.2021.824776.","journal-title":"Front Mol Biosci"},{"key":"2332_CR80","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096\u2013106. https:\/\/doi.org\/10.1056\/NEJMoa1712191.","journal-title":"N Engl J Med"},{"key":"2332_CR81","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/liv.14495","volume":"40","author":"Y Seko","year":"2020","unstructured":"Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, et al. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver Int. 2020;40:1686\u201392. https:\/\/doi.org\/10.1111\/liv.14495.","journal-title":"Liver Int"},{"key":"2332_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070619","volume":"11","author":"T Motomura","year":"2021","unstructured":"Motomura T, Amirneni S, Diaz-Aragon R, Faccioli LAP, Malizio MR, Coard MC, et al. Is HSD17B13 genetic variant a protector for liver dysfunction? Future perspective as a potential therapeutic target. J Pers Med. 2021;11:619. https:\/\/doi.org\/10.3390\/jpm11070619.","journal-title":"J Pers Med"},{"key":"2332_CR83","doi-asserted-by":"publisher","first-page":"194","DOI":"10.14218\/JCTH.2020.00151","volume":"9","author":"W-Y Liu","year":"2021","unstructured":"Liu W-Y, Eslam M, Zheng KI, Ma H-L, Rios RS, Lv M-Z, et al. Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in Chinese patients with metabolic-associated fatty liver disease. J Clin Transl Hepatol. 2021;9:194\u2013202. https:\/\/doi.org\/10.14218\/JCTH.2020.00151.","journal-title":"J Clin Transl Hepatol"},{"key":"2332_CR84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1556\/2060.2021.00183","volume":"108","author":"G Rezamand","year":"2021","unstructured":"Rezamand G, Mahmoudi T, Tabaeian SP, Farahani H, Shahinmehr F, Nobakht H, et al. The GG genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease. Physiol Int. 2021;108:342\u201352. https:\/\/doi.org\/10.1556\/2060.2021.00183.","journal-title":"Physiol Int"},{"key":"2332_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.15403\/jgld-2703","volume":"30","author":"SP Tabaeian","year":"2021","unstructured":"Tabaeian SP, Mahmoudi T, Sabzikarian M, Rezamand G, Dabiri R, Nobakht H, et al. The Leu72Met (rs696217 G\u2009>\u2009T) Polymorphism of the Ghrelin Gene Might Be a Protective Factor for Nonalcoholic Fatty Liver Disease. J Gastrointestin Liver Dis. 2021;30:233\u20139. https:\/\/doi.org\/10.15403\/jgld-2703.","journal-title":"J Gastrointestin Liver Dis"},{"key":"2332_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)01108-0","volume":"82","author":"MR Troppmair","year":"2025","unstructured":"Troppmair MR, Oberhuber L, Forer L, Schoenherr S, Glodny B, Henninger B, et al. Fri-455-yi the impact of donor and recipient HSD17B13, PNPLA3 and TM6SF2 genotype on post-transplant fibrosis, steatosis and survival in liver transplant recipients. J Hepatol. 2025;82:S375. https:\/\/doi.org\/10.1016\/S0168-8278(25)01108-0.","journal-title":"J Hepatol"},{"key":"2332_CR87","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/jgh.14056","volume":"33","author":"BK Koo","year":"2018","unstructured":"Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease: Additive effects of PNPLA3 and TM6SF2. J Gastroenterol Hepatol. 2018;33:1277\u201385. https:\/\/doi.org\/10.1111\/jgh.14056.","journal-title":"J Gastroenterol Hepatol"},{"key":"2332_CR88","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","volume":"104","author":"I M\u00edkov\u00e1","year":"2020","unstructured":"M\u00edkov\u00e1 I, Ne\u0159oldov\u00e1 M, Hub\u00e1\u010dek JA, Dlouh\u00e1 D, Jirsa M, Honsov\u00e1 E, et al. Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation. 2020;104:526\u201334. https:\/\/doi.org\/10.1097\/TP.0000000000002876.","journal-title":"Transplantation"},{"key":"2332_CR89","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.aohep.2018.10.005","volume":"18","author":"M Xu","year":"2019","unstructured":"Xu M, Li Y, Zhang S, Wang X, Shen J, Zhang S. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China. Ann Hepatol. 2019;18:456\u201360. https:\/\/doi.org\/10.1016\/j.aohep.2018.10.005.","journal-title":"Ann Hepatol"},{"key":"2332_CR90","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","volume":"13","author":"M Longo","year":"2022","unstructured":"Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, et al. TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. Cell Mol Gastroenterol Hepatol. 2022;13:759\u201388. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.11.007.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"2332_CR91","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/hep.31238","volume":"72","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybj\u00e6rg\u2010Hansen A, Stender S. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology. 2020;72(3):845\u201356. https:\/\/doi.org\/10.1002\/hep.31238.","journal-title":"Hepatology"},{"key":"2332_CR92","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"N Santoro","year":"2012","unstructured":"Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55:781\u20139. https:\/\/doi.org\/10.1002\/hep.24806.","journal-title":"Hepatology"},{"key":"2332_CR93","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00439-013-1294-3","volume":"132","author":"T Kitamoto","year":"2013","unstructured":"Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132:783\u201392. https:\/\/doi.org\/10.1007\/s00439-013-1294-3.","journal-title":"Hum Genet"},{"key":"2332_CR94","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14218\/JCTH.2021.00067","volume":"10","author":"K Xu","year":"2022","unstructured":"Xu K, Zheng KI, Zhu P-W, Liu W-Y, Ma H-L, Li G, et al. Interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis. J Clin Transl Hepatol. 2022;10:219\u201329. https:\/\/doi.org\/10.14218\/JCTH.2021.00067.","journal-title":"J Clin Transl Hepatol"},{"key":"2332_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.035","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F, et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.035.","journal-title":"J Hepatol"},{"key":"2332_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103549","volume":"25","author":"MJ Ramos","year":"2022","unstructured":"Ramos MJ, Bandiera L, Menolascina F, Fallowfield JA. In vitro models for non-alcoholic fatty liver disease: emerging platforms and their applications. iScience. 2022;25:103549. https:\/\/doi.org\/10.1016\/j.isci.2021.103549.","journal-title":"iScience"},{"key":"2332_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02616-x","volume":"4","author":"T Kostrzewski","year":"2021","unstructured":"Kostrzewski T, Snow S, Battle AL, Peel S, Ahmad Z, Basak J, et al. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol. 2021;4:1080. https:\/\/doi.org\/10.1038\/s42003-021-02616-x.","journal-title":"Commun Biol"},{"key":"2332_CR98","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMe2206291","volume":"388","author":"AL Beam","year":"2023","unstructured":"Beam AL, Drazen JM, Kohane IS, Leong T-Y, Manrai AK, Rubin EJ. Artificial Intelligence in Medicine. N Engl J Med. 2023;388:1220\u20131. https:\/\/doi.org\/10.1056\/NEJMe2206291.","journal-title":"N Engl J Med"},{"key":"2332_CR99","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cgh.2024.08.009","volume":"23","author":"P Udompap","year":"2025","unstructured":"Udompap P, Liu K, Attia IZ, Canning RE, Benson JT, Therneau TM, et al. Performance of AI-enabled electrocardiogram in the prediction of metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2025;23:574-582.e3. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.009.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2332_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050722","volume":"17","author":"N Pugliese","year":"2025","unstructured":"Pugliese N, Bertazzoni A, Hassan C, Schattenberg JM, Aghemo A. Revolutionizing MASLD: how artificial intelligence is shaping the future of liver care. Cancers (Basel). 2025;17:722. https:\/\/doi.org\/10.3390\/cancers17050722.","journal-title":"Cancers (Basel)"},{"key":"2332_CR101","doi-asserted-by":"publisher","unstructured":"Qin Y, Chhetri P, Theusch E, Lim G, Teker S, Kuang Y-L et al. Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem Cells. bioRxiv. 2025;:2025.01.13.632567. https:\/\/doi.org\/10.1101\/2025.01.13.632567","DOI":"10.1101\/2025.01.13.632567"},{"key":"2332_CR102","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001065","author":"LAP Faccioli","year":"2024","unstructured":"Faccioli LAP, Sun Y, Animasahun O, Motomura T, Liu Z, Kurihara T, et al. Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000001065.","journal-title":"Hepatology"},{"key":"2332_CR103","doi-asserted-by":"publisher","unstructured":"Xia M, Varmazyad M, Palacin IP, Gavlock DC, Debiasio R, LaRocca G, et al. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. bioRxiv. 2024:2024.04.22.590608. https:\/\/doi.org\/10.1101\/2024.04.22.590608.","DOI":"10.1101\/2024.04.22.590608"},{"key":"2332_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403516","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H, Yin G, Kohlhepp MS, Schumacher F, Hundertmark J, Hassan MIA, et al. Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model. Adv Sci. 2024;11:e2403516. https:\/\/doi.org\/10.1002\/advs.202403516.","journal-title":"Adv Sci"},{"key":"2332_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1423936","author":"M Xia","year":"2024","unstructured":"Xia M, Varmazyad M, Pla-Palac\u00edn I, Gavlock DC, DeBiasio R, LaRocca G, et al. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. Front Cell Dev Biol. 2024. https:\/\/doi.org\/10.3389\/fcell.2024.1423936.","journal-title":"Front Cell Dev Biol"},{"key":"2332_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.165209","volume":"519","author":"J Li","year":"2025","unstructured":"Li J, Wu Z, Gan J, Zhi Y, Zhao Y, Li L. Engineering microfluidic human liver-islet crosstalk platform for recapitulating MASLD. Chem Eng J. 2025;519:165209. https:\/\/doi.org\/10.1016\/j.cej.2025.165209.","journal-title":"Chem Eng J"},{"key":"2332_CR107","doi-asserted-by":"publisher","first-page":"S462","DOI":"10.1016\/S0168-8278(25)01306-6","volume":"82","author":"T Payo-Seraf\u00edn","year":"2025","unstructured":"Payo-Seraf\u00edn T, Mart\u00ednez-Geijo J, M\u00e9ndez-Blanco C, San-Miguel B, Garc\u00eda-Palomo A, Ortiz-de-Urbina JJ, et al. SAT-112 role of hypoxia on the progression and survival of hepatocellular carcinoma in hypoxia-inducible factor 1 alpha knockout bi- and tri-dimensional in vitro models. J Hepatol. 2025;82:S462. https:\/\/doi.org\/10.1016\/S0168-8278(25)01306-6.","journal-title":"J Hepatol"},{"key":"2332_CR108","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","volume":"82","author":"HY Kim","year":"2025","unstructured":"Kim HY, Rosenthal SB, Liu X, Miciano C, Hou X, Miller M, et al. Multi-Modal analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease. J Hepatol. 2025;82:882\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.044.","journal-title":"J Hepatol"},{"key":"2332_CR109","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023113898","volume":"42","author":"A Hess","year":"2023","unstructured":"Hess A, Gentile SD, Ben Saad A, Rahman R-U, Habboub T, Pratt DS, et al. Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease. EMBO J. 2023;42:e113898. https:\/\/doi.org\/10.15252\/embj.2023113898.","journal-title":"EMBO J"},{"key":"2332_CR110","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41586-025-08850-1","volume":"641","author":"HA Reza","year":"2025","unstructured":"Reza HA, Santangelo C, Iwasawa K, Reza AA, Sekiya S, Glaser K, et al. Multi-zonal liver organoids from human pluripotent stem cells. Nature. 2025;641:1258\u201367. https:\/\/doi.org\/10.1038\/s41586-025-08850-1.","journal-title":"Nature"},{"key":"2332_CR111","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","volume":"41","author":"D Hendriks","year":"2023","unstructured":"Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nat Biotechnol. 2023;41:1567\u201381. https:\/\/doi.org\/10.1038\/s41587-023-01680-4.","journal-title":"Nat Biotechnol"},{"key":"2332_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/science.adu9375","volume":"388","author":"OJ Abilez","year":"2025","unstructured":"Abilez OJ, Yang H, Guan Y, Shen M, Yildirim Z, Zhuge Y, et al. Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization. Science. 2025;388:eadu9375. https:\/\/doi.org\/10.1126\/science.adu9375.","journal-title":"Science"},{"key":"2332_CR113","doi-asserted-by":"publisher","first-page":"N\/A","DOI":"10.20517\/mtod.2024.105","volume":"5","author":"T Feng","year":"2025","unstructured":"Feng T, Li J, Ma X, Ye J. Mini liver organoid models emulating metabolic dysfunction-associated steatotic disease development: gradually emerging beneath the iceberg. Metab Target Organ Damage. 2025;5:N\/A-N\/A. https:\/\/doi.org\/10.20517\/mtod.2024.105.","journal-title":"Metab Target Organ Damage"},{"key":"2332_CR114","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1039\/d5lc00221d","volume":"25","author":"GM Balachander","year":"2025","unstructured":"Balachander GM, Ng IC, Pai RR, Mitra K, Tasnim F, Lim YS, et al. LEADS - a comprehensive human liver-on-a-chip for non-alcoholic steatohepatitis (NASH) drug testing. Lab Chip. 2025;25:3444\u201366. https:\/\/doi.org\/10.1039\/d5lc00221d.","journal-title":"Lab Chip"},{"key":"2332_CR115","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ25-0140","author":"M Fujimoto","year":"2025","unstructured":"Fujimoto M, Tanaka T. Advancing liver metabolic zonation with single-cell and spatial omics. Endocr J. 2025. https:\/\/doi.org\/10.1507\/endocrj.EJ25-0140.","journal-title":"Endocr J"},{"key":"2332_CR116","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/hep4.1976","volume":"6","author":"CE Thomas","year":"2022","unstructured":"Thomas CE, Diergaarde B, Kuipers AL, Adibi JJ, Luu HN, Chang X, et al. NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population. Hepatol Commun. 2022;6:2310\u201321. https:\/\/doi.org\/10.1002\/hep4.1976.","journal-title":"Hepatol Commun"},{"key":"2332_CR117","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen Y, Du X, Kuppa A, Feitosa MF, Bielak LF, O\u2019Connell JR, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet. 2023;55:1640\u201350. https:\/\/doi.org\/10.1038\/s41588-023-01497-6.","journal-title":"Nat Genet"},{"key":"2332_CR118","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender S, Kozlitina J, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49:842\u20137. https:\/\/doi.org\/10.1038\/ng.3855.","journal-title":"Nat Genet"},{"key":"2332_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)01524-7","volume":"82","author":"M Masarone","year":"2025","unstructured":"Masarone M, Motta BM, Torre P, Lombardi M, Sarcina T, Coppola R, et al. WED-451 comparison of the pathophysiology of \u201cmetabolic\u201d and \u201cgenetic\u201d MASLD: a multiOmics cohort study. J Hepatol. 2025;82:S562. https:\/\/doi.org\/10.1016\/S0168-8278(25)01524-7.","journal-title":"J Hepatol"},{"key":"2332_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040855","volume":"13","author":"I Milani","year":"2025","unstructured":"Milani I, Chinucci M, Leonetti F, Capoccia D. MASLD: prevalence, mechanisms, and sex-based therapies in postmenopausal women. Biomedicines. 2025;13:855. https:\/\/doi.org\/10.3390\/biomedicines13040855.","journal-title":"Biomedicines"},{"issue":"5","key":"2332_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.04.007","volume":"233","author":"M-Y Miao","year":"2025","unstructured":"Miao M-Y, Han W-W, Lyu J-Q, Liu Z-Y, Jiang W, Zhang Z, et al. Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data. Am J Obstet Gynecol. 2025;S0002-9378(25)00212-1. https:\/\/doi.org\/10.1016\/j.ajog.2025.04.007.","journal-title":"Am J Obstet Gynecol"},{"key":"2332_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1567573","volume":"16","author":"J Meyer","year":"2025","unstructured":"Meyer J, Teixeira AM, Richter S, Larner DP, Syed A, Kl\u00f6ting N, et al. Sex differences in diet-induced MASLD \u2013 are female mice naturally protected? Front Endocrinol (Lausanne). 2025;16:1567573. https:\/\/doi.org\/10.3389\/fendo.2025.1567573.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2332_CR123","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf018","volume":"46","author":"J Dong","year":"2025","unstructured":"Dong J, Dennis KMJH, Venkatakrishnan R, Hodson L, Tomlinson JW. The impact of estrogen deficiency on liver metabolism; implications for hormone replacement therapy. Endocr Rev. 2025;bnaf018. https:\/\/doi.org\/10.1210\/endrev\/bnaf018.","journal-title":"Endocr Rev"},{"key":"2332_CR124","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"LA Aaltonen","year":"2020","unstructured":"Aaltonen LA, Abascal F, Abeshouse A, Aburatani H, Adams DJ, Agrawal N, et al. Pan-cancer analysis of whole genomes. Nature. 2020;578:82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6.","journal-title":"Nature"},{"key":"2332_CR125","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050275","volume":"16","author":"C Molina-Aguilar","year":"2023","unstructured":"Molina-Aguilar C, Robles-Espinoza CD. Tackling the lack of diversity in cancer research. Dis Model Mech. 2023;16:dmm050275. https:\/\/doi.org\/10.1242\/dmm.050275.","journal-title":"Dis Model Mech"},{"key":"2332_CR126","doi-asserted-by":"publisher","unstructured":"Zhang H, Wu X, Ni W, Wu J, Zhou S, Jia L et al. Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. J Adv Res. 2025;:S2090-1232(25)00658-7. https:\/\/doi.org\/10.1016\/j.jare.2025.08.042","DOI":"10.1016\/j.jare.2025.08.042"},{"key":"2332_CR127","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41588-025-02229-8","volume":"57","author":"J German","year":"2025","unstructured":"German J, Yang Z, Urbut S, Vartiainen P, Natarajan P, Patorno E, et al. Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design. Nat Genet. 2025;57:1620\u20137. https:\/\/doi.org\/10.1038\/s41588-025-02229-8.","journal-title":"Nat Genet"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-026-02332-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:09:10Z","timestamp":1781636950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-026-02332-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1186\/s12920-026-02332-7","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors (CMA, FGAG, FJCC, MDM, MH, DJA, CDRE).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}